Summary by Moomoo AI
KEYSTONE PHARMACEUTICAL-B (THE “COMPANY”) ANNOUNCED ITS RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023 WITH A TOTAL REVENUE OF RMB463.8 MILLION, A DECREASE OF 3.6% COMPARED TO THE SAME PERIOD LAST YEAR. Among them, pharmaceutical sales revenue was RMB336.7 million, and license fee revenue and royalty fee revenue increased 8.6% year-over-year to RMB127.1 million. R&D expenses decreased by RMB86.4 million to RMB527.8 million from the same period last year, mainly due to lower milestone fees and third-party contract costs and employee costs. Administrative expenses were also reduced to RMB182.7 million. The loss for the year amounted to RMB367.2 million, a decrease of 59.3% from last year. The Company did not distribute dividends during the reporting period and was not involved in any significant litigation or arbitration.